Article
Otorhinolaryngology
Lillian W. W. Dattilo, Vinay K. K. Rathi, Rodney J. J. Schlosser, Zachary M. M. Soler, George A. A. Scangas, Alan D. D. Workman, Stacey T. T. Gray
Summary: Between January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion. Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30%.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
(2023)
Article
Immunology
Alison D. Petro, Joseph Dougherty, Bryant R. England, Harlan Sayles, Michael J. Duryee, Carlos D. Hunter, Joel M. Kremer, Dimitrios A. Pappas, William H. Robinson, Jeffrey R. Curtis, Geoffrey M. Thiele, Ted R. Mikuls
Summary: In rheumatoid arthritis patients, the number of positive autoantibodies is dose-dependently associated with treatment response to biologics, with anti-CCP antibody positivity having the strongest impact.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Gastroenterology & Hepatology
Virginia Solitano, Antonio Facciorusso, Dermot P. B. Mcgovern, Tran Nguyen, Ruben J. Colman, Lily Zou, Brigid S. Boland, Silje W. Syversen, Kristin Kaasen Jorgensen, Christopher Ma, Alessandro Armuzzi, Aze Wilson, Vipul Jairath, Siddharth Singh
Summary: This study evaluated the association between HLA-DQA1*05 genotype and the risk of immunogenicity with TNF-a antagonists in patients with IMIDs. The meta-analysis showed that patients with HLA-DQA1*05 variants had a 75% higher risk of immunogenicity compared to non-carriers. The study also found that patients with HLA-DQA1*05 variants had a higher risk of secondary loss of response.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Natalia Mena-Vazquez, Marta Rojas-Gimenez, Carmen Maria Romero-Barco, Sara Manrique-Arija, Espildora Francisco, Maria Carmen Aguilar-Hurtado, Isabel Anon-Onate, Lorena Perez-Albaladejo, Rafaela Ortega-Castro, Francisco Javier Godoy-Navarrete, Inmaculada Urena-Garnica, Maria Luisa Velloso-Feijoo, Rocio Redondo-Rodriguez, Francisco Gabriel Jimenez-Nunez, Blanca Panero Lamothe, Maria Isabel Padin-Martin, Antonio Fernandez-Nebro
Summary: This study describes a cohort of patients with RA-ILD and identifies risk factors associated with disease progression and mortality. Most patients with RA-ILD maintained stable lung function while one-third experienced worsening or died. Identifying factors related to worsening in RA-ILD is crucial for clinical management.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Immunology
Uday Raj Sharma, Akhila Nediyedath Rathnakaran, B. P. Prudhvi Raj, Gayathry Padinjakkara, Akanksh Das, Surendra Vada, Manjunatha P. Mudagal
Summary: Rheumatoid arthritis is an autoimmune inflammatory disorder characterized by joint destruction and symmetrical symptoms. Pregnancy has a positive effect on RA, with different hypotheses explaining this. Treatment options for RA include the use of DMARDs and NSAIDs.
INFLAMMOPHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Soo-Kyung Cho, Sun-Young Jung, Hyoungyoung Kim, Yeo-Jin Song, Kyungeun Lee, Yoon-Kyoung Sung
Summary: Since the introduction of biosimilar TNFis in 2012, their usage has steadily increased among RA patients in Korea, leading to a decrease in medical costs for both originator and biosimilar TNFis users.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2021)
Article
Health Care Sciences & Services
Yongkang Zhang, James H. Flory, Yuhua Bao
Summary: This study found an association between nonadherence to chronic medications and potentially preventable healthcare utilization and spending. Improving medication adherence is a potential avenue to reducing preventable utilization and spending. However, the impact of nonadherence on preventable healthcare utilization and spending is more significant among racial/ethnic and low socioeconomic groups.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Review
Medicine, General & Internal
Yoshiya Tanaka
Summary: Rheumatoid arthritis is a systemic autoimmune disease that causes bone and cartilage destruction and systemic osteoporosis. Treatments targeting tumor necrosis factor and Janus kinase inhibitors can prevent structural damage, while osteoporosis can be treated with bisphosphonates and anti-receptor activator of the nuclear factor-kappa B ligand antibody. Understanding the mechanisms underlying osteoporosis and joint destruction in rheumatoid arthritis can lead to improved care and new treatments.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Natalia Mena-Vazquez, Marta Rojas-Gimenez, Clara Fuego-Varela, Aimara Garcia-Studer, Nair Perez-Gomez, Carmen Maria Romero-Barco, Francisco Javier Godoy-Navarrete, Sara Manrique-Arija, Myriam Gandia-Martinez, Jerusalem Calvo-Gutierrez, Pilar Morales-Garrido, Coral Mourino-Rodriguez, Patricia Castro-Perez, Isabel Anon-Onate, Francisco Espildora, Maria Carmen Aguilar-Hurtado, Ana Hidalgo Conde, Rocio Arnedo Diez de los Rios, Eva Cabrera Cesar, Rocio Redondo-Rodriguez, Maria Luisa Velloso-Feijoo, Antonio Fernandez-Nebro
Summary: The study aims to evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). The results showed that abatacept can stabilize pulmonary function and joint inflammation in most patients, and it has a favorable safety profile.
Article
Rheumatology
Anna Shin, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song, Seoyoung C. Kim, Eun Ha Kang
Summary: This study aimed to compare tuberculosis (TB) risk during biologics treatment among rheumatoid arthritis (RA) patients in Korea who underwent chemoprophylaxis and those who did not after pre-biologic latent TB screening. The results showed that patients who received chemoprophylaxis had a lower TB risk compared to those who did not, indicating the importance of preventive strategies for TB in screening-negative patients receiving biologics.
Article
Rheumatology
Yoshiya Tanaka, Ayako Yamaguchi, Toshiaki Miyamoto, Kazuhide Tanimura, Hideyuki Iwai, Yuko Kaneko, Tsutomu Takeuchi, Koichi Amano, Naoki Iwamoto, Atsushi Kawakami, Miho Murakami, Norihiro Nishimoto, Tatsuya Atsumi, Takayuki Sumida, Koichiro Ohmura, Tsuneyo Mimori, Hisashi Yamanaka, Keishi Fujio, Yoshihisa Fujino, Kazuyoshi Saito, Kazuhisa Nakano, Shintaro Hirata, Shingo Nakayamada
Summary: In patients with rheumatoid arthritis who achieved sustained remission, continuing treatment, dose reduction, or discontinuation of methotrexate and dose reduction of biologic disease-modifying antirheumatic drugs (bDMARDs) achieved comparable disease control after one year. Subsequent de-escalation of methotrexate had no impact on disease control but decreased adverse events in year two.
Article
Urology & Nephrology
Hironari Hanaoka, Jun Kikuchi, Kazuoto Hiramoto, Shuntaro Saito, Yasushi Kondo, Yuko Kaneko
Summary: This study investigated the incidence and factors associated with the progression of chronic kidney disease (CKD) in patients with stable rheumatoid arthritis (RA). The results showed that controlling inflammation contributes to inhibiting CKD progression in RA patients.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Oncology
Douglas J. Rupert, Alyssa M. Jordan, Marina A. Ziemian, Rachel M. Brown, Neil S. Fleming, R. Craig Lefebvre
Summary: Healthcare providers in the US have limited understanding and cautious attitudes towards biosimilars, perceiving them as less safe and effective than original biologics. Their concerns stem from uncertainty about how biosimilarity is defined and operationalized, negative experiences with generic drugs, unfamiliarity with the FDA's approval pathway for biosimilars, skepticism towards the abbreviated approval process, and concerns about pharmacy substitution.
Article
Health Care Sciences & Services
Miranda B. Lam, Tynan H. Friend, Parsa Erfani, E. John Orav, Ashish K. Jha, Jose F. Figueroa
Summary: ACOs did not significantly impact overall spending for patients in the last 6 months of life, except for hospice care utilization.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Rui Hu, Tao Yuan, Hui Wang, Jianglin Zhao, Liya Shi, Quankai Li, Chunmei Zhu, Na Su, Shengzhao Zhang
Summary: This meta-analysis found that etanercept biosimilars were more effective than reference biologics (Enbrel) in terms of ACR50 response rate for treating active rheumatoid arthritis, while other outcomes related to efficacy, safety, and immunogenicity were comparable between etanercept biosimilars and the originator.
FRONTIERS IN PHARMACOLOGY
(2023)